{"id":"W4410037857","doi":"10.1002/pbc.31692","title":"A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors","year":2025,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Eisai","keywords":"Medicine; Lenvatinib; Everolimus; Internal medicine; Refractory (planetary science); Rhabdomyosarcoma; Oncology; Response Evaluation Criteria in Solid Tumors; Adverse effect; Renal cell carcinoma; Population; Pazopanib; Phases of clinical research; Ramucirumab; Cancer; Sarcoma; Toxicity; Pathology; Thyroid cancer; Sunitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001585964,0.001224141,0.001633645,0.0003909218,0.0003099452,0.0006952523,0.0007096711,0.000722469,0.002270472],"category_scores_gemma":[0.0006986803,0.0005093036,0.0009467631,0.0003765433,0.0005773261,0.0005343734,0.0002779586,0.002136112,0.0005294449],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007598741,"about_ca_system_score_gemma":0.001554678,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007507771,"about_ca_topic_score_gemma":0.002258868,"domain_scores_codex":[0.9995723,0.0002253628,0.00002957698,0.00005953868,0.00004586634,0.00006730064],"domain_scores_gemma":[0.9994097,0.00006614708,0.0001511032,0.00004735079,0.00004446465,0.0002813223],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6151936,0.1620069,0.01707589,0.001128328,0.002173921,0.0006933244,0.0005048651,0.003183664,0.07925042,0.0003766738,0.003391471,0.1150209],"study_design_scores_gemma":[0.3867679,0.5846759,0.01839115,0.00003821962,0.0004887159,0.0006647874,0.00006848707,0.000905979,0.004957935,0.0001207114,0.002897223,0.00002298756],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956387,0.001110396,0.0003327085,0.0001838255,0.00003718202,0.001617916,0.0004637783,0.00003798992,0.0005775041],"genre_scores_gemma":[0.9873383,0.00216098,0.003033194,0.0005602588,0.0001379333,0.003118729,0.001757832,0.00002830063,0.001864531],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002270472,"threshold_uncertainty_score":0.008387446,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01252591367402572,"score_gpt":0.3284036317164102,"score_spread":0.3158777180423845,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}